Biohaven Ltd. (BHVN) Stock Score, Valuation & Financial Research

Biohaven Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BHVN

Biohaven Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 12.08. These figures are a research snapshot, not a buy or sell recommendation.

What Biohaven Ltd. does

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Biohaven is a clinical-stage biopharmaceutical company that generates value through the discovery, development, and commercialization of proprietary therapeutics. Its business model relies on advancing a pipeline of drug candidates in immunology, neuroscience, and oncology, currently focusing on clinical-stage programs while seeking to monetize its intellectual property through future commercialization or strategic partnerships.

Products and services

Biohaven's portfolio includes clinical and preclinical programs such as Kv7 ion channel modulators for epilepsy and mood disorders, extracellular protein degradation platforms for immunological diseases, and myostatin-activin pathway targeting agents for neuromuscular and metabolic conditions.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, drug substance manufacturing, and product development services. Specific supplier names are not disclosed. Source

Business strengths to evaluate

Proprietary drug development platforms Source
Experienced drug development leadership Source

Business risks and research considerations

Clinical trial failure and regulatory approval uncertainty Source
Dependence on third-party manufacturers and service providers Source
Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BHVN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 12.08
Market capitalization:: 1.82B (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -586.84M
Free cash flow:: USD -610.15M
Cash:: USD 238.03M
Total debt:: USD 297.04M
EPS:: USD -4.64

What stands out

Free cash flow is USD -610.15M, negative for the stored period.
The balance sheet shows USD 238.03M of cash versus USD 297.04M of total debt, with debt exceeding cash on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Debt exceeds cash by USD 59M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BHVN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can BHVN fund negative free cash flow using its current cash position before it may need more debt or new shares?
Does BHVN's balance between cash and debt leave enough flexibility if business conditions weaken?
What specifically needs to improve for BHVN to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of BHVN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BHVN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.